IP Library Granted Patent US 9,689,014
Granted Patent B2
US 9,689,014 · App. 14/368,513 · Granted Jun 27, 2017

Use of lysozyme as a tag

Inventors: Stefan Haertle (Jensenwang, DE); Sebastian Jaeger (Graefelfing, DE); Daniela Daubert (Olching, DE)
Assignee: MORPHOSYS AG
C12P21/00C07K1/22C12N15/62C12P21/02C07K2319/00C07K2319/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,689,014
App. No.
14/368,513
Granted
Jun 27, 2017
Kind
B2
Abstract

The present disclosure provides a method to express and purify polypeptides and proteins. In the present disclosure the use of lysozyme as a fusion partner is disclosed. Furthermore, purification methods to isolate lysozyme-tagged polypeptides and proteins via lysozyme-specific antibodies are described. More specifically, the present disclosure provides a method to express and purify monomeric polypeptides and proteins by using lysozyme as a tag.

Claims (11)

1. A method for the production of an isolated monomeric polypeptide or protein, said method comprising the steps of

(a) expressing said monomeric polypeptide or protein as a fusion protein in a host cell, wherein said fusion protein comprises said monomeric polypeptide or protein and lysozyme, and wherein said fusion protein is secreted from the host cell into cell culture supernatant; and

(b) isolating said secreted fusion protein from the cell culture supernatant.

2. The method according to claim 1 , wherein the yield of said fusion protein is at least 2-fold higher than the yield compared to the monomeric polypeptide or protein not comprising lysozyme.

3. The method according to claim 1 , wherein less than 15% of the fusion protein comprising the monomeric polypeptide or protein and lysozyme forms aggregates.

4. The method according to claim 1 , wherein said host cell is a prokaryotic cell or a eukaryotic cell.

5. The method according to claim 1 , wherein said host cell was transfected with an expression vector encoding said fusion protein comprising the monomeric polypeptide or protein, and lysozyme.

6. The method according to claim 1 , wherein said monomeric polypeptide or protein has a length of at least 100 amino acids.

7. The method according to claim 1 , wherein said fusion protein is isolated with an antibody specific for lysozyme.

8. The method according to claim 1 , wherein said lysozyme is a mammalian lysozyme.

9. The method according to claim 1 , wherein said lysozyme is a fragment, analogue, homologue, variant or derivative of lysozyme.

Assignments (2)
EXCERPT OF COMMERCIAL REGISTER REFLECTING NEW ADDRESS Recorded May 26, 2017
From: MORPHOSYS AG
To: MORPHOSYS AG
Reel/Frame 042587/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: HAERTLE, STEFAN, DR.; JÄGER, SEBASTIAN, DR.; DAUBERT, DANIELA, DR.
To: MORPHOSYS AG
Reel/Frame 035176/0904 →
Priority Claims (1)
EP 12152095 · Jan 23, 2012 · regional
Continuity (2)
Provisional Application 61589408 · Jan 23, 2012
Related Publication 20140349343A1 · Nov 27, 2014